Potential T-cell Lymphoma Treatment Withdrawn During Phase III Testing

Following an interim look at data from an ongoing phase III trial, Takeda Oncology has ended the development of alisertib as a possible treatment for patients with peripheral T-cell lymphoma (PTCL).

Alisertib, previously known as MLN8237, was being studied as a kinase inhibitor in PTCL patients that could stop cancer cell proliferation. The phase III trial was investigating the compound's ability to do better than the standard of care in these patients with regard to progression-free survival, or the length of time following treatment before the disease began to progress again.

Alisertib was previously being developed by Millennium Pharmaceuticals before that company was bought by Takeda.

This doesn't mean the end of alisertib, as there is also an ongoing phase II trial against small cell lung cancer, and even earlier-stage trials against other non-Hodgkin lymphomas as well as some solid tumor cancers.

"While we are disappointed that alisertib will not be further investigated for relapsed or refractory peripheral T-cell lymphoma, we are optimistic about alisertib's clinical development program in small cell lung cancer," said Takeda Oncology chief Michael Vasconcelles. "The randomized Phase II study of alisertib in small cell lung cancer will continue as planned and is currently underway."

Source: FierceBiotech

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap